Integra LifeSciences (IART) Q3 Earnings Report: Key Insights to Anticipate
Integra LifeSciences Earnings Report: Integra LifeSciences is set to report its earnings, with analysts expecting an 8.8% year-on-year revenue growth to $414.2 million and adjusted earnings of $0.43 per share.
Recent Performance and Analyst Sentiment: The company previously beat revenue expectations by 5.2% but missed EPS guidance; analysts have maintained their estimates, indicating stable expectations heading into the earnings report.
Peer Comparisons: Competitors in the healthcare equipment sector have shown varied results, with Intuitive Surgical achieving significant revenue growth while Neogen experienced a decline, reflecting mixed market conditions.
Investor Sentiment and Stock Performance: Positive investor sentiment has led to a 6.1% average increase in share prices in the sector, with Integra LifeSciences up 14.2% recently, and analysts have set an average price target of $16.38 for the stock.
Get Free Real-Time Notifications for Any Stock
Analyst Views on IART
About IART
About the author

Integra LifeSciences Faces Recall Due to Packaging Defects Linked to 11 Serious Injuries
- FDA Alert: The FDA has issued an early alert regarding potentially high-risk issues with Integra LifeSciences' MediHoney wound and burn care products, citing packaging and production failures that could lead to infection and compromise patient safety.
- Product Recall: Integra has notified customers to immediately cease the use of all MediHoney wound and burn products and specific lots of CVS Wound Gel, ensuring these products are removed from clinical settings to prevent further harm.
- Injury Reports: As of December 19, 2025, Integra reported 11 serious injuries linked to MediHoney products and three serious injuries associated with CVS Wound Gel, highlighting the severity of safety concerns despite no reported fatalities.
- Distributor Instructions: Integra instructed distributors to halt further distribution of affected products and manage customer communications directly, ensuring that impacted products are properly handled, reflecting the company's commitment to customer safety.

Integra LifeSciences CEO to Present at 44th Annual J.P. Morgan Healthcare Conference
- Conference Participation: Integra LifeSciences CEO Mojdeh Poul and CFO Lea Knight will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, showcasing the company's latest advancements in medical technology, which is expected to attract investor interest.
- Live Webcast: The presentation will be available via live webcast on Integra LifeSciences' investor relations website, enabling global investors to access real-time updates on the company, thereby enhancing transparency and investor confidence.
- Company Mission: Integra LifeSciences is committed to restoring patients' lives through innovative treatment pathways, demonstrating its leadership in surgical, neurologic, and regenerative care, which further solidifies its competitive position in the market.
- Brand Portfolio: The company offers a comprehensive portfolio of high-quality leadership brands aimed at meeting the evolving market demands through continuous innovation and high standards of medical solutions, driving long-term growth.









